A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Ganetespib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2017 Planned End Date changed from 1 Sep 2016 to 7 Jul 2019.
- 01 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2016, as reported by ClinicalTrials.gov.
- 01 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.